Fair Value (Details Textual)
|
|
|
12 Months Ended |
|
|
|
|
|
|
|
|
|
Jul. 07, 2020
USD ($)
|
Apr. 08, 2020
USD ($)
$ / shares
|
Dec. 31, 2021
CAD ($)
|
Dec. 31, 2021
USD ($)
|
Dec. 31, 2020
USD ($)
shares
|
Dec. 31, 2021
USD ($)
$ / shares
|
Oct. 05, 2021
USD ($)
|
Oct. 30, 2020
$ / shares
|
Sep. 01, 2020
shares
|
Jun. 30, 2020
USD ($)
|
Jun. 09, 2020
USD ($)
|
Jan. 15, 2020
$ / shares
|
Feb. 08, 2018
$ / shares
shares
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Principal amount |
|
|
|
|
|
|
$ 20,000,000
|
|
|
|
$ 17
|
|
|
| Fair value of the contingent consideration |
|
|
|
|
|
$ 6,300,000
|
|
|
|
|
|
|
|
| Purchase price |
|
|
|
|
|
|
$ 18,000,000
|
|
|
|
$ 15
|
|
|
| Settled value of the contingent consideration |
|
|
|
|
$ 0
|
|
|
|
|
|
|
|
|
| Gain on settlement of the contingent consideration liability |
|
|
|
|
$ 998,000
|
|
|
|
|
|
|
|
|
| Purchase price per unit | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
$ 9
|
|
| Shares sold | shares |
|
|
|
|
309,286
|
|
|
|
4,798,271
|
|
|
|
|
| Exchange ratio of converted warrants upon conversion |
|
|
1.00%
|
1.00%
|
|
|
|
|
|
|
|
|
|
| IPO [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of securities called by each warrant or right | shares |
|
|
|
|
|
|
|
|
|
|
|
|
1
|
| Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued | shares |
|
|
|
|
|
|
|
|
|
|
|
|
189,365
|
| Common Stock [Member] | IPO [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase price per unit | $ / shares |
|
|
|
|
|
|
|
$ 2.4
|
|
|
|
|
|
| Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price | $ / shares |
|
|
|
|
|
$ 11.5
|
|
|
|
|
|
|
|
| Number of securities called by each warrant or right | shares |
|
|
|
|
|
|
|
|
|
|
|
|
1
|
| Warrant [Member] | IPO [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase price per unit | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
$ 10
|
| Trellis Solutions, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of the contingent consideration |
|
|
|
|
|
$ 998,000
|
|
|
|
$ 0
|
|
|
|
| Settled value of the contingent consideration |
|
$ 3,529
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase price per unit | $ / shares |
|
$ 7.24
|
|
|
|
|
|
|
|
|
|
|
|
| Solo Sciences, Inc. [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Description of contingent consideration |
|
|
(i) $0.01 per solo*TAGTM and solo*CODETM sold or (ii) 7% of net revenue. The fees were to be paid annually until the earlier of: (1) our shares trading above $12 per share for any consecutive 20 trading days in a 30-day period; (b) upon our no longer owning a majority stake in Solo; or (c) upon expiration of the patents related to solo*TAGTM and solo*CODETM, which is December 1, 2029.
|
(i) $0.01 per solo*TAGTM and solo*CODETM sold or (ii) 7% of net revenue. The fees were to be paid annually until the earlier of: (1) our shares trading above $12 per share for any consecutive 20 trading days in a 30-day period; (b) upon our no longer owning a majority stake in Solo; or (c) upon expiration of the patents related to solo*TAGTM and solo*CODETM, which is December 1, 2029.
|
|
|
|
|
|
|
|
|
|
| Fair value of the contingent consideration |
|
|
|
|
|
389,000
|
|
|
|
|
|
|
|
| Settled value of the contingent consideration |
|
$ 17,939
|
|
$ 0
|
|
|
|
|
|
|
|
|
|
| Gain on settlement of the contingent consideration liability |
|
|
|
|
$ 389,000
|
|
|
|
|
|
|
|
|
| Ample Organics [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Description of contingent consideration |
|
|
The contingent consideration amount is reduced by an amount equal to the product of CAD$6.67 multiplied by the difference between CAD$9,000,000and the amount of Recurring Revenue realized during the twelve months following the acquisition.
|
The contingent consideration amount is reduced by an amount equal to the product of CAD$6.67 multiplied by the difference between CAD$9,000,000and the amount of Recurring Revenue realized during the twelve months following the acquisition.
|
|
|
|
|
|
|
|
|
|
| Fair value of the contingent consideration |
|
|
$ 10,000,000
|
|
|
$ 604,000
|
|
|
|
|
|
|
|
| Settled value of the contingent consideration |
$ 31,531
|
|
|
$ 0
|
|
|
|
|
|
|
|
|
|
| Gain on settlement of the contingent consideration liability |
|
|
|
$ 604,000
|
|
|
|
|
|
|
|
|
|
| Recurring revenue recognized |
|
|
$ 9,000,000
|
|
|
|
|
|
|
|
|
|
|
| Mtech [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of securities called by each warrant or right | shares |
|
|
|
|
|
|
|
|
|
|
|
|
1
|
| Mtech [Member] | IPO [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued | shares |
|
|
|
|
|
|
|
|
|
|
|
|
5,750,000
|
| Purchase price per unit | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
$ 10
|
| Shares sold | shares |
|
|
|
|
|
|
|
|
|
|
|
|
750,000
|
| Exercise price | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
$ 11.5
|
| Mtech [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase price per unit | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
$ 10
|
| Shares sold | shares |
|
|
|
|
|
|
|
|
|
|
|
|
243,750
|
| Exercise price | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
$ 11.5
|
| Mtech [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of securities called by each warrant or right | shares |
|
|
|
|
|
|
|
|
|
|
|
|
1
|